BMS to pay up to $936m for NG-348.
Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market
Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
FDA calls for hold after reports of bleeding.
BMS to refocus operations, according to Q3 results.
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.